Fig. 1: Distribution of molecular and cytogenetic alterations between real and synthetic patients. | npj Digital Medicine

Fig. 1: Distribution of molecular and cytogenetic alterations between real and synthetic patients.

From: Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Fig. 1

50 molecular genetic and cytogenetic alterations were included in generative modeling. Molecular genetics were originally assessed by next-generation sequencing using a targeted myeloid panel including genes that encode for epigenetic regulators (a, dark blue), the cohesion complex (b, orange), transcription factors (c, red), NPM1 and TP53 (d, light blue), signaling factors (e, purple), and the spliceosome (f, green). Cytogenetic aberrations (g, black) were selected based on previously demonstrated impact on patient outcomes. Distributions for all variables are denoted as percentages of each respective cohort. Overall, both synthetic cohorts well represented the distribution of alterations in the original cohort with only slight deviations denoted by highly statistically significant (p < 0.001) differences in BCORL1, DNMT3A, PHF6, and ZRSR2 for NFlow, as well as CUX1 and GATA2 for CTAB-GAN + .

Back to article page